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Abstract
Genetic studies (in particular linkage and association studies) identify chromosomal regions involved in a disease or
phenotype of interest, but those regions often contain many candidate genes, only a few of which can be followed-up for
biological validation. Recently, computational methods to identify (prioritize) the most promising candidates within a region
have been proposed, but they are usually not applicable to cases where little is known about the phenotype (no or few
confirmed disease genes, fragmentary understanding of the biological cascades involved). We seek to overcome this
limitation by replacing knowledge about the biological process by experimental data on differential gene expression
between affected and healthy individuals. Considering the problem from the perspective of a gene/protein network, we
assess a candidate gene by considering the level of differential expression in its neighborhood under the assumption that
strong candidates will tend to be surrounded by differentially expressed neighbors. We define a notion of soft
neighborhood where each gene is given a contributing weight, which decreases with the distance from the candidate gene
on the protein network. To account for multiple paths between genes, we define the distance using the Laplacian
exponential diffusion kernel. We score candidates by aggregating the differential expression of neighbors weighted as a
function of distance. Through a randomization procedure, we rank candidates by p-values. We illustrate our approach on
four monogenic diseases and successfully prioritize the known disease causing genes.
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Introduction
Genetic studies, including cytogenetic, linkage, and association
studies, can identify chromosomal regions associated with a disease
or phenotype of interest. Similarly, high-throughput ‘omics’
experiments identify genes or proteins implicated in a biological
process of interest. In both cases, biologists are often confronted
with long lists of tens or hundreds of candidate genes among which
they need to select a limited number of candidates for further
validation. This problem has been termed gene prioritization [1].
Recently, computational methods for prioritizing candidate genes
have been proposed. They usually rank candidates by matching
their information across multiple data sources against a profile
derived from a set of genes, pathways, or biological processes
already known to be involved in the phenotype. A frequent
objection to this class of methods is that they cannot be applied to
cases where little is known about the molecular basis of the
phenotype (no confirmed disease genes, fragmentary understand-
ing of the biological cascades involved). We seek to overcome this
limitation by replacing knowledge about the biological process by
experimental data on differential gene expression between affected
and healthy individuals. Considering the problem from the
perspective of a gene/protein network, we assess a candidate
gene by considering the level of differential expression in its
neighborhood under the assumption that strong candidates will tend
to be surrounded by differentially expressed neighbors.
A number of methods are currently available for gene
prioritization. Aerts et al. (2006) developed ENDEAVOUR, a gene
prioritization method that ranks candidate genes based on their
similarity to genes already involved in the biological process of
interest, using multiple data sources (e.g., sequence, expression,
literature) [2]. Similarly, Ko ¨hler et al. (2008) developed GeneWan-
derer, a method for prioritizing candidate genes by the use of the
random walk analysis that defined similarities in protein-protein
interactions (PPI) networks [3]. Their global distance measure
defines the similarity between genes within the global network and
ranks candidate genes on the basis of their similarity to known
disease genes. They hypothesized that a global network-similarity
measure captures associations between disease proteins better than
algorithms based on direct interactions or shortest paths between
disease genes. Franke et al. (2006) also incorporated the interactions
between genes in a network to prioritize candidate genes [4]. They
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genes and their functions. Their method, Prioritizer, ranks
candidate genes on the basis of their interactions. They analyze
susceptibility loci and investigate whether genes from different loci
can be linked to each other. Lage et al. (2007) developed a
phenome-interactome network that integrates phenotypic litera-
ture information from OMIM with a cross-species PPI network
[5]. They implemented a Bayesian disease gene predictor that
computes for each candidate gene the probability that it is the
disease-related gene. High probabilities are assigned to genes that
interact with genes that are already associated with phenotypically-
related disorders. Chuang et al. (2007) developed a network analysis
method by applying a protein network-based approach that
identifies biomarkers not as individual genes but as subnetworks
extracted from protein interaction databases [6]. To find
associations between phenotypes and subnetworks, they developed
a scoring based on mutual information measure. Although their
methodology resembles that of gene prioritization, their method is
related to biomarker discovery rather than prioritization.
Most of available prioritization methods have in common that
they require knowledge about the disease to identify putative
disease genes, for example in the form of a set of genes, pathways,
or gene ontology categories known to be implicated in the disease.
They then rank candidate genes through ‘‘guilt by association’’
methods across a variety of data sources. But when nothing or only
little is known about a disease, these methods will be inapplicable
or ineffective. While it is extremely useful to incrementally add
disease genes to phenotypes whose molecular basis is reasonably
well characterized, there is strong demand from geneticists for
methods that could help in the more difficult case of disorders for
which the molecular basis is not yet elucidated. Currently, there
are not yet truly effective prioritization methods for this case.
We seek to overcome this limitation by replacing knowledge
about the biological process by experimental data on differential
gene expression between affected and healthy individuals. Our
method is a generalization, from a systems biology perspective, of
a standard procedure for assessing candidate genes in genetic
studies. A standard genetic procedure to analyze candidate genes
is to check the expression level of a candidate gene in patient-
derived material against wild type (typically in fibroblast or
immortalized lymphoblastoid cell lines). Candidates for which a
significant difference is observed between the two groups are
considered promising. However, for many genetic diseases (such as
diseases arising from point mutations in coding regions), there is no
guarantee that the expression level of the disease gene itself is
affected (although this is possible through feedback effects).
Rather, genes ‘‘downstream’’ of the disease gene are those whose
expression will be affected. Instead of considering genes in
isolation, we consider the differential expression data now at the
level of a gene/protein network. If we look at expression patterns
mapped on a gene network, we therefore expect that we will
observe a disrupted expression module around the disease gene.
Other candidate genes, which are not causally related to the
phenotype, should not be part of such a disrupted expression
module. For this reason, the entire affected neighborhood has to
be considered for each candidate gene instead of only taking its
own expression level into account.
When considering the expression data at the network level, we
need to rely on a gene/protein network. Originally, protein-
protein interaction networks from data on putative physical
interaction between proteins. More recently, protein networks
combining a variety of information sources have been proposed. A
link in such a network does not necessarily imply physical
interaction between two proteins, but rather some form of
association resulting from different types of data (actual interac-
tion, membership in the same pathway, coexpression, literature
cooccurrence, etc.) We will call such a network, a protein
association network, or protein network for short. Note that in
such networks no distinction is made between gene and protein, or
multiple isoforms. Furthermore, protein networks are far from
complete, and dealing with direct protein-protein interactions may
be suboptimal since protein networks are still sparse because of
many unknown components and pathways [4,7]. Also, procedures
that define neighborhoods in terms of the minimum number of
steps from a given gene suffer from the ‘‘small world’’ effect (i.e.,
the number of neighbors of a given gene grows rapidly with the
number of steps taken along the network). To overcome those
potential limitations, we chose to use a global distance network
that considers both direct and indirect paths in the network [3]. By
considering indirect interactions in a protein network, missing links
in the network can be compensated. Thus, a global distance
network is more densely connected than the sparse protein
network from which it is derived. Specifically, our method derives
the global distance network from a functional protein association
network (STRING [8]) using kernel methods. STRING integrates
both protein-protein interactions as well as predicted interactions
based on comparative genomics and text mining [8].
Figure 1 shows an overview of our approach. For each gene in
the network, its differential expression level is determined by
transcriptome-wide microarray experiments of mutant vs. wild-
type lines. Then differentially expressed neighborhoods in this
network are considered for all candidate genes from a chromo-
somal region of interest (e.g., identified in a linkage study).
Candidate genes with genes in their neighborhood having highly
differentially expressed levels are strong candidates. The neigh-
borhood of a candidate gene is defined by direct connections in the
global distance network, whereby its size can vary. The smaller the
distance from a neighboring gene to the candidate, the closer the
neighboring gene is in the network. We have chosen to work with
the notion of a soft neighborhood by which we mean that the
neighborhood of a gene is not a limited set of gene, but rather a
weighting function that decreases monotonically as a function of
the distance from the gene, but potentially covers the whole
network (this idea is reminiscent of the idea of fuzzy membership
in fuzzy c-means clustering).
To identify candidates belonging to a significantly disrupted
expression module, we have developed a novel randomization
method that identifies modules with significantly affected genes.
Each candidate receives a score based on the analysis of the
differential expression along its neighborhood. The level of
differential expression of each gene is weighted by its network
distance from the candidate and summed up over all genes.
Therefore, the higher the differential expression levels of
neighboring genes with small distances are, the higher the score.
To determine a candidate gene’s significance, a p-value based on a
randomization procedure is computed. If a candidate belongs to a
significant disrupted expression module in the network, its p-value
is expected to be significant.
Evaluating such a method in silico is obviously challenging
because if we make predictions on actual diseases where no genes
are known, the only way to validate those predictions will be to
carry out a full biological validation. Moreover, the kind of
expression data needed for our analysis will be currently available
only for very few diseases because at this point biologists mostly
carry out this type of experiments for diseases for which the cause
is known. In a first step, we therefore mimic the situation by taking
known disease genes for which expression data for patients versus
controls is available and attempt to recover the gene mutated in
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could successfully prioritize the disease-causing gene for each data
set. The average rank of the known disease genes was approx. 4
out of approx. 120 candidate genes (see Results). Thus, our
method can detect unknown disease causing genes by identifying
the most disrupted expression modules in the global distance
network. In a second step, using one of the only available human
expression data sets for a disorder of unclear etiology, we have
applied our method to the polygenic disorder Stein-Levental
syndrome for which no disease gene is known. We could confirm
the influence of two candidate genes: fibrillin 3 (FBN3, for which a
susceptibility allele has been identified) and follistatin (FST, for
which association with a Stein-Levental syndrome related
metabolic phenotype has been shown). Finally, we suggest a new
candidate gene (DEAD box 4) potentially involved in this disease.
Results
Our distance network was derived from the STRING database
[8], from which we used all data types provided (genomic context,
high-throughput experiments, coexpression data, and previous
knowledge). The resulting network detects all direct and indirect
connections of genes and represents a notion of global distance
measure (see Materials and Methods).
We illustrate our method by its application to the analysis of
constitutional genetic disorders caused by a single gene mutation.
Following the current practice of assessing candidate gene
expression in EBV cell lines or fibroblast cultures in mutant
against wild type, we consider expression data from such biological
material (or other accessible tissue biopsies). There is however only
a limited number of such data sets publicly available through the
ArrayExpress [9] and Gene Expression Omnibus [10] repositories.
We present here the results of the method on four case studies.
We distributed all signals randomly over the network to estimate
the significance of the candidates. In an adequate data set, at least
one gene should be found with a significant p-value (i.e., p,0.05).
We then assessed how high the actual disease gene ranked and
whether its score was significant.
Case studies
We have evaluated our approach on four data sets: (1) fragile X
syndrome (FXS) [11] caused by mutation of FMR1 (fragile X
mental retardation 1), (2) Marfan syndrome (MFS) [12] caused by
mutation of FBN1 (fibrillin 1), (3) cystic fibrosis (CF) [13] caused by
mutation of CFTR, and (4) Becker muscular dystrophy (BMD)
[14] caused by mutation of DMD.
For each data set, we have determined a set of candidate genes
by taking the genes within a set of chromosomal bands centered on
the disease-causing or disease-related gene to gather approx. 120
genes. Genes that were absent in our distance network were not
further considered. For finding differentially expressed genes in the
network we computed the fold-change for each gene in the
genome (see Materials and Methods). Beside the scores of the
candidates and the fold-change derived from the microarray
experiments, we also present known links to similar diseases with
related phenotypes.
Each data set and the high-ranking candidates (i.e., those that
have a significant p-value) that are phenotypically linked to related
diseases [15–21] are characterized in the Supplementary Materials
S1. This demonstrates the significance of the method and shows
Figure 1. Overview of the method. (1) From a protein association network a global distance network is computed based on a kernel method
(e.g., the Laplacian exponential diffusion kernel). (2) A disease related microarray experiment is required from which the differential expression levels
of all genes in the network are determined. (3) The differential expression levels of the genes are mapped on the global distance network. (4) A set of
candidate genes is required (e.g., from a linkage study). (5) For each candidate gene its differentially expressed neighborhood is identified by a
regression analysis. (6) Based on the regression analysis each candidate gene receives a score. (7) The candidate genes are ranked by their scores.
doi:10.1371/journal.pone.0005526.g001
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also related genes that may also be involved in this disease.
Neighborhood
Determining an adequate size for the neighborhood that
influences the score of a candidate is a challenge and influences
the ranking. For three data sets (fragile X syndrome, Marfan
syndrome and Cystic fibrosis) we have determined small
neighborhoods of 150 or 20 neighboring genes, because for these
data sets we obtained the best signal for small neighborhoods (data
not shown) after applying the Fisher omnibus statistics (see
Materials and Methods for more details). However, for one data
set (Becker muscular dystrophy) we have determined a larger
neighborhood of 2000 neighboring genes due to high signal for a
large neighborhood (data not shown).
To illustrate the difference between disrupted expression
neighborhoods of significant candidate genes and not significant
genes, we have added graphs containing the queried neighbor-
hood of the candidates (Figures S1, S2, S3). These graphs show the
differential expression levels of the neighbors and their distances to
the candidate gene. We can observe that the closest neighborhood
of a significant candidate is highly differentially expressed and
belongs to a more disrupted expression module than the
neighborhood of a nonsignificant candidate.
Significance
To determine a candidate gene’s significance, the differential
expression levels are distributed randomly over the network. The
candidate’s score is compared with the distribution of the
randomly generated scores that leads to a p-value. If a candidate’s
score is larger than 95% of all randomized scores, this candidate
gene can be considered as belonging to a significant disrupted
expression module in the network.
Figure 2 shows for all data sets the distribution of p-values after
10,000 randomizations, and the p-values of the disease genes
whereby all were assigned significant p-values. These plots
demonstrate that a clear distinction could be made between
significant genes with low p-values and all other genes, and that the
disease genes could be identified by their significant p-values and
their high ranking.
Ranking
Tables S1, S2, S3, S4 show the results of the ranking of the
evaluation data sets. In all four benchmark data sets, the disease
causing genes were ranked in the top 10 (FXS: 1
st position, MFS:
5
th position, CF: 7
th position, BMD: 2
nd position) out of lists
containing approximately 120 candidate genes (see Supplementary
Material), and all were assigned significant p-values. For all data
sets, we could identify several disrupted expression modules of
different sizes around a candidate gene. For two data sets (FXS
and CF), some of the top ranked genes were already known to be
directly associated with a related disease or phenotype [15–21]
that emphasizes the significance of this result. We could not only
successfully identify the disease genes, but also genes that correlate
with the corresponding phenotype.
One of our aims was to develop a method that is independent of
the differential expression levels of a candidate gene itself.
Therefore, for evaluation purposes, we did not take the differential
expression levels of the candidates into account but, preferably, the
levels of their neighboring genes. Although in practice, we should
obviously take into account the differential expression level of the
candidate itself (because the disease gene can be disrupted through
feedback effects). Our rankings in Tables S1, S2, S3, S4
demonstrate clearly that the ranking orders do not depend on
the up- or down-regulation of the candidate genes themselves, but
rather on the effects of being positioned in their neighborhoods.
Thus, genes that are not differentially expressed can rank higher
than highly differentially expressed genes as long as their
neighborhood is differentially expressed.
Application to Stein-Levental syndrome
We have applied our approach to the Stein-Levental syndrome
[22], which is characterized by obesity, hyperandrogenism, and
chronic anovulation in women. Stein-Levental syndrome is an
endocrine disorder that affects approximately 5% of women and is
a leading cause of infertility. This syndrome is believed to be
oligogenic (i.e., caused by the effect of a limited number of genes)
rather than monogenic [23]. Follistatin (FST) was originally
proposed as a candidate for Stein-Levental syndrome by linkage
and association studies [24], but is now thought to be rather
associated with key androgenic phenotypes of Stein-Levental
syndrome but not with the disease itself. These results suggest the
existence of another disease-causing gene for Stein-Levental
syndrome in the vicinity of FST (rather than FST itself). Recently,
a Stein-Levental syndrome susceptibility locus was identified at
19p13.2 [25] and further association studies have suggested
fibrillin 3 (FBN3) as the Stein-Levental syndrome susceptibility
locus [26]. However, beside FST and FBN3 other candidate genes
have been studied, often with inconsistent results [27].
We have determined two sets of candidate genes located on the
chromosomal region of FST (chr5q11.2) and FBN3 (chr19p13.2).
Both genes (FST, FBN3) were ranked high by our method (Tables
S5, S6) and we could confirm their important role in this disease.
We further detected the DEAD box 4 gene that is located on
chr5q11.2 and that was ranked on the top position with a
significant p-value (Table S5). We suggest that DEAD box 4 is a
new candidate gene for Stein-Levental syndrome because of
association with stem cell recruitment to the ovaries, interaction
with the microRNA processing machinery, and impact on
apoptosis [28–35].
Discussion
As mentioned in the introduction, there are several known
methods to prioritize candidate genes. These approaches can be
split into methods that need known disease-gene associations about
the disease [2,3,5] and methods without this precondition [4]. If
little knowledge is available for a specific disease, the methods that
require known disease genes will be ineffective. Franke et al. (2006)
presented a method to prioritize candidate genes without a
training set [4], but without using expression data to evaluate the
candidate genes. Among a set of disease loci, they will look for
pairs, triples, etc. of genes at different loci for which interaction has
been described. Such sets of interacting genes are considered more
likely candidates for causing the disease at the different loci.
Because of the combinatorial nature of the test, the method does
not have high statistical power. Along other lines, Chuang et al.
(2007) introduced a network analysis method using expression
data [6]. However, they focused on finding active subnetworks and
biomarkers in cancer and developing a methodology that is not
directly related to our problem. Our strategy differs as we focused
on searching for disease genes for which genetic mutation causes
constitutional disorders.
The strength and uniqueness of our approach is that we
substitute disease-specific experimental data (in our case expres-
sion data) for the prior knowledge of the molecular basis of the
disorder. ENDEAVOUR [2] could also incorporate disease-
specific expression data but did not use any network analysis
Identifying Disease Genes
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of known genes for the disease. Among all other methods, only
Chuang et al. (2007) leverages experimental data [6], however with
an entirely different scope and method. Essentially, although
existing methods could be applied on the known benchmark cases,
none of them would be directly applicable to the actual situation
where we want to use our method, which is when the molecular
basis of the disease is unknown (with the case of Stein-Levental
syndrome as an illustration).
A first question is in which setups our method is applicable. We
have chosen here to apply our method in a setup where a locus is
known for the disease. Although this is not a strict requirement and
genes can be prioritized on a genomewide basis, it has the
advantage of limiting the number of candidates tested and
therefore limiting the number of false positives. It also guarantees
that at least one gene must be associated with the disease.
However, among genetic studies, while the method is relevant to
linkage and association studies, it may not be applicable to loci
detected by cytogenetic studies of patients with genomic deletions
or duplications. Indeed, in this case, multiple genes are affected by
a copy number change, so that the expression data can be
expected to be the superposition of the downstream effects of all
the affected genes (although it could be that most of the phenotype
is explained by a single critical gene that dominates the
downstream cascade of expression dysregulation, in which case
the method may still be applicable). Although the concept of our
method may seem at first tailored to monogenic disorders, it is
more broadly applicable. This is demonstrated by our case study
on the polygenic disorder Stein-Levental syndrome, where we
could detect FBN3 and FST as related to the disease.
Several factors influence the performance of our prioritization
method. First, the quality and coverage of the network around the
Figure 2. Histogram of p-values from randomizations vs. p-values of the disease genes FMR1, FBN1, CFTR, and DMD. This figure
displays the histogram of p-values obtained after 10,000 randomizations, and the p-values of the disease-causing genes from all four benchmark data
sets. It can be observed that in all data sets only a small set of genes have significant p-values (i.e., they belong to disrupted expression modules) and
all disease causing genes are among them.
doi:10.1371/journal.pone.0005526.g002
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isolated gene with no edges in the network can never be effectively
prioritized by our method (except by relying solely on its own
expression data). We have chosen to use the STRING database
(version 7.1) because it is built by taking into account multiple
heterogeneous data sources. This results in a large network with a
good coverage (human: 16,050 genes, mouse: 16,566 genes).
Errors in the network (caused by incorrect gene annotation,
unreliable functional annotation, etc.) may both cause false
negatives (missing the disease gene) as false positives (genes
incorrectly identified as promising because of incorrect association
with other genes). Continuing improvements in the quality of
protein association networks will contribute to increased effective-
ness of the proposed method. Moreover, protein association
networks are naı ¨ve in terms of alternative transcripts of genes and
protein isoforms. At this moment, no distinction is possible among
them. It is also unclear what the quality and coverage of
nonprotein-coding genes is in current protein association networks
– although our candidate gene DEAD box 4 for Stein-Levental
syndrome suggests a possible role for the nonprotein-coding genes
PIWIL2 (MILI) and DICER1. Several alternatives exist to the
STRING network including BioGRID, IntAct, IntNetDb, HPRD,
and Dip, and we will study the impact on performance of the
choice of network in follow-up work.
Second, the quality and the relevance of the expression data will
greatly influence the results of the method. Poorly collected
samples (patients not actually sharing the same molecular
phenotype) or disease heterogeneity (multiple genes or pathways
leading to similar phenotypes) will obscure the expression pattern
and will make picking up a meaningful signal more difficult.
Similarly, lack of access to the most relevant cell types (biopsies
cannot be performed arbitrarily on patients) can be a limiting
factor for the method. If the relevant molecular cascades are
simply not active in the cell type assessed, differences in expression
may be meaningless. The idea is that the pattern of differential
expression is as concentrated as possible on the network so that the
affected subnetworks can be effectively identified. Some mutations
may lead to extensive downstream cascades that may be reflected
in network patterns that are too broad to effectively pinpoint the
disease-causing gene. A promising experimental direction for
focusing the expression patterns towards the disease-causing gene
would be to use more sophisticated factorial disease for the
microarray experiment. If we can identify a stimulus that is
incorrectly processed in affected individuals (e.g., a metabolite or a
protein), we could attempt to perform an expression profiling
experiment where patient and control material receive a treatment
that triggers the affected cascades. The differential expression
response will tend be more tightly focused towards those genes that
are essential for the difference in response to the treatment
between affected vs. non-affected individuals.
Third, an important parameter of the method is the
neighborhood size or, the scale parameter of our weighting
function that defines it. To study the neighborhood of the
candidate genes in order to identify disrupted expression modules
in the distance network, we had to bound the neighborhood to a
limited size because the network was very densely connected, and
thus the neighborhood of a candidate gene consisted of almost all
genes in the network. This limitation was done by only considering
the neighboring genes with the smallest distances to the candidate
(any gene further than a certain threshold was not considered). We
wanted the size of the neighborhood to be dependent on the
disruption we found in the network. We determined this size by
analyzing the observed signals obtained by applying the Fisher
omnibus statistic to the list of candidate genes for different
neighborhood sizes, and choosing the size for which we caught the
best signal as the most reliable one. For three data sets (FXS, MFS,
CF), we determined a small neighborhood because we observed
best signal for small neighborhoods (data not shown). However, for
the fourth data set (BMD), we determined a larger neighborhood
because we could not observe a strong signal for smaller
neighborhoods (data not shown). Therefore, we had to expand
the number of neighboring genes that were taken into account for
finding highly differentially expressed neighborhoods. This
difference showed us that the size of the neighborhood can differ
and is dependent on the number of affected genes in the disease
and their biological pathways.
If we chose a neighborhood size for which we caught a weak
signal, the ranking could produce an unreliable result. For
example, b=0.5 for FXS [11] that leads to a neighborhood size
of 20 genes (see Table S9) would capture no meaningful signal
from the neighbors and would lead to an unreliable ranking.
Instead, a ranking for which a strong signal regarding to the
significance is observed can be seen as a reliable result. Many
factors influence the selection of an optimal neighborhood size: the
shape of the weighting window, the density of the network (i.e.,
average node degree), the choice of the index of differential
expression (here, the logarithm of the fold change), and so on.
Further optimization of all the parameters will be necessary to
devise an optimal procedure for neighborhood size selection.
Fourth, technical details of the mathematical model could have
a substantial influence on the performance. Our purpose was to
identify all direct and indirect connections in the functional
protein association network from STRING that leads to a densely
connected (global distance) network. We computed the Laplacian
Exponential Diffusion Kernel [36] to obtain a global distance
network. Following Fouss et al. (2006), there exists several kernels
on graphs, such as the Exponential Diffusion Kernel, the
regularized Laplacian Kernel, the von Neumann Diffusion
Kernel, and the Commute Time Kernel [37]. We chose the
Laplacian Exponential Diffusion Kernel because Ko ¨hler et al. (2008)
already applied this kernel as a good performing kernel to
construct a distance network [3]. Furthermore Fouss et al. (2006)
observed that this kernel performs systematically better than their
corresponding adjacency matrix-based kernels (Exponential Dif-
fusion Kernel, von Neumann Diffusion Kernel) [37]. However, a
more systematic assessment on the effect of the kernel and its
comparison to shortest-path, direct-interaction-only, or other
methods, such as GTOM [38] is certainly in order. To efficiently
compute the kernel matrix we applied the Cholesky Decomposi-
tion (see Materials and Methods) because the naı ¨ve computation
was too time consuming. However, by calculating the Cholesky
Decomposition we could compute the kernel method successfully
with full accuracy (see Tables S7, S8). As a measure for
determining the change in expression of a gene we chose the
fold-change between control and experiment [39]. It is a
commonly used measure (e.g., [11–14]), but numerous alternatives
exist and will be compared in future work, such as differential
expression indices expressed in terms of z-scores or log p-values, or
combining the differential expression level and its statistical
significance.
There are certainly diseases for which the candidate genes show
no significances (i.e., there are no significant p-values that
distinguish significant from not significant genes). In this case the
disease does not lead to detectable disrupted expression modules
or affected pathways in the network. Although it would be
preferable to detect the disease gene, the ability of the method to
return a negative result is an asset of the method. Indeed the
performance is greatly influenced by the quality of the expression
Identifying Disease Genes
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gene, and the underlying biology (i.e., existence of actually
disrupted expression modules) so that the method cannot be
expected to work optimally on every disorder. Therefore, the
ability to assess statistical significant and potentially return a
negative result (i.e., ‘‘no strong candidate found’’) makes it possible
to avoid pursuing ‘‘best’’ candidates that are actually not
promising. There are also cases for which our method does return
significant genes among which the known disease causing gene can
however not be found. For those cases, one or several disrupted
expression modules are found but none of them is centered on the
disease-causing gene. This can be explained by the fact that even a
single-gene disorder can result in the disruption of several
pathways (downstream of the original pathway), making therefore
the signal we are looking for more difficult to detect. This reflects
that the current method is not suitable for all single gene disorders.
We applied our approach to Stein-Levental syndrome [22] and
could identify two important candidate genes (FST and FBN3)
from two different chromosomal regions [23–26]. We further
detected the DEAD box 4 gene that is located on chr5q11.2 and
that was ranked on the top position with a significant p-value.
DEAD box polypeptide 4 (synonyms Mvh and Vasa) is an RNA
helicase and is used commonly as a marker for germline cells
[28,29]. Although little is know about the molecular function of
DEAD box 4 in mammals, there are several reasons why Dead
box 4 is a plausible candidate gene for Stein-Levental syndrome.
First, in male mice loss of Dead box 4 results in infertility due to
suspension of premeiotic differentiation of spermatogenic cells
[30]. Female knockout mice do not show any obvious reproductive
defects, but it is plausible that the effect may be less dramatic in
females, leading only to a (partial) arrest in follicle development.
One of the genes that fail to be expressed in a mouse Dead box 4
knockout is Aven, a caspase inhibitor [29]. Failure to express Aven
thus may result in altered apoptosis control. Stein-Levental
syndrome is characterized by follicular arrest, where several
follicles develop to a size of 5–7 mm but not further. Since primary
follicles secrete androgens, too many arrested follicles likely lead to
elevated androgen levels, a hallmark of Stein-Levental syndrome.
Second, DEAD box 4 interacts with Dicer1 and is colocalized with
MILI [31]. Dicer1 processes miRNA precursors to mature
miRNAs which are incorporated in the RISC complex. These
miRNA-RISC complexes then exert a broad posttranscriptional
control on many mRNAs. Mili belongs to the Piwi family, encodes
a component of the RISC complex and is expressed at early stages
of oocyte growth [32] and crucial for progression through
spermatogenesis [33]. In Drosophila, the loss of Piwi function
leads to the failure of germline cyst formation [34]. As a third
potential mechanism, altered DEAD box 4 may influence stem cell
recruitment to the ovaries. Johnson et al. have demonstrated that
stem cells from bone marrow and peripheral blood which are also
marked with the presence of DEAD box 4, can migrate to the
ovaries of sterilized females and give rise to oocyte-containing
follicles. Interestingly, the level of DEAD box 4 is influenced by the
estrous cycle [35].
In summary, we have developed a novel gene prioritization
approach that substitutes expression data to prior knowledge of the
molecular basis of the disease, as required by existing methods.
Our method ranks candidate genes by their differentially
expressed neighborhoods. We have developed an efficient
algorithm to compute a genomewide network by applying the
Cholesky decomposition. To illustrate the power of our method,
we have applied it to four constitutional genetic disorders and
successfully prioritized the known disease-causing genes. In an
application on a genetic disorder that is not yet well studied, we




A network model based on the STRING database [8] was built
for human genes. This sparse network model was used to compute
distances between single genes via the Laplacian Exponential
Diffusion Kernel [36]. The goal of such an approach is to build a
network model based on global similarity measure (i.e., to include
both direct and indirect connections between genes).
For each disease, a set of candidate genes (e.g., from a linkage
study) has to be defined and a relevant microarray experiment is
required (e.g., diseased sample vs. reference sample). A main issue
that arises when applying kernel graph methods to genomewide
networks is the computing time. To reduce it, the kernel matrices
were approximated by the full or incomplete Cholesky decompo-
sition and the reduced eigenvalue decomposition. Knowing the
distances between single genes in the network, the differential
expression level of adjacent genes can be considered. Each
candidate gene receives a score based on the analysis of the
differentially expressed neighborhoods, by which it is ranked.
Candidate genes with genes in their neighborhood having highly
differentially expressed indices are strong candidates.
Functional protein association network
A protein association network is an undirected graph with
proteins as nodes and weights as edges. If there exists an
association between two proteins, an edge will be set between
the corresponding nodes in the graph. The weights of the edges
are taken represent the probability that such an association exists
in reality. To model our functional protein association network, we
used data from STRING [8] (version 7.1). STRING is a database
of known and predicted protein-protein interactions. The
interactions are derived from different information sources and
different organisms, whereas the interactions include physical and
functional associations. To build our networks, we have used the
fused network provided by STRING that already integrates all
available protein-protein interactions.
Kernel matrix and distance network
We hypothesize that global network-similarity measures capture
relationships between disease proteins better than algorithms
based on direct interactions. To capture global relationships within
a graph, a graph kernel was used. A graph kernel computes the
global similarity of two nodes as the probability of reaching one
node at some time point after a random walk starting from another
node. This global similarity detects, besides direct, also indirect
connections in the graph. The resulting graph leads to a global
distance network where the edge between two nodes does not
represent a direct interaction, but rather the global distance in this
network.
The Laplacian Exponential Diffusion Kernel was intro-






   n
~ebL ð1Þ
whereby L is the Laplacian matrix of a weighted and undirected
graph G with symmetric weights [36,37], and the parameter b is the
diffusion parameter that determines the degree of diffusion (for
more details see Supplementary Materials). For a Laplacian matrix,
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matrix. It can be seen as a random walk, starting from a node and
transitioning to a neighboring node with the probability b.
The complexity of Equation (1 is On 3   
. To improve the
performance of the computation of such a diffusion, we can apply
the Cholesky decomposition, that is decomposing the Laplacian
matrix into the product of a lower triangular matrix by its
transpose, before computing the kernel from this matrix. In this
way, the computing time is reduced significantly as presented in
Table S7.
The resulting kernel matrix is a densely connected network.
This new network detects not only the direct interaction from the
original protein association network, but also all indirect
interactions via other genes. Thanks to this property the distances
between all genes in the network can be determined. They are
necessary for identifying highly expressed neighborhoods with a
certain distance from a candidate gene, even if the genes are not
directly interacting.
Cholesky decomposition
There exists for every symmetric positive definite matrix A of
rank n exactly one lower triangular matrix S~ sij
  
with sij~0 if
ivj and sijw0 if i=1, 2,…, n.
The Cholesky decomposition (CD) solves the linear equation
A:x~b by transforming A into a product of a lower triangular
matrix S of rank n and its transposed ST:
A~S:ST ð2Þ
To reduce the dimensionalities of kernel matrices we applied the
Incomplete Cholesky decomposition (ICD) with pivoting [40–42].
ICD is an iterative algorithm that approximates a lower rank
matrix (m%n) in order to reduce the dimensionalities so that
A&~ S S:~ S ST,[Rn|m, m%n ð3Þ
The resulting matrix ~ S S is a lower triangular matrix of rank m. The
overall complexity is Om 2n
  
and the storage requirement is
Om n ðÞ .
Distance network
Having a symmetric and positive semidefinite Laplacian matrix
L, we can compute the Laplacian Exponential Diffusion Kernel by
applying CD or ICD instead of Equation (1), the computing time
can be reduced significantly from On 3   
to On 2m
  
, in which m is
the rank of S (Equations 2–3)).
In Table S7, we show that the computing time in calculating the
Laplacian Exponential Diffusion Kernel can be significantly
reduced by applying the CD. If we can accept an approximation
to the exact kernel, we can apply the ICD by defining a threshold
to reduce the rank of the matrices. In our example, we chose a
threshold that led to an error of 7%–10%, depending on the size of
the matrix (Table S8). The error is the difference of the norm of
the reduced rank matrix and of the full rank matrix. For a network
of the whole human genome containing 16,566 genes and an error
of 7%, the resulting matrix got a low rank matrix with a rank of
1,829 that could be computed in 35 minutes, whereas by running
the computation by applying the initial equation introduced by
Kondor and Lafferty (2002) [36] (Equation (1)), the computation on
the same machine (dual Opteron 250 with 16 GB RAM) ran out
of memory and could not finish the computation. Even if no error
can be handled and the CD is applied, and thus the matrices
remain full rank, the computation could be successfully finished
after 32 hours.
Gene expression analysis
After obtaining a global distance network by computing the
Laplacian Exponential Diffusion Kernel from the protein
association network, the gene expression profiles for a specific
disease can be mapped onto this network. For this purpose,
relevant genome-wide microarray experiment data (e.g., disease
sample vs. reference sample) is required from which the differential
expression level for each gene in the genome is computed. Basing
on the microarray experiment (the datasets that we chose from
GEO were from good quality and already normalized) the fold
change between the two conditions can be computed for each
gene. We applied the fold-change between control and experiment
[39]. For our method only the absolute value of the fold-change is
relevant (i.e., if a gene is highly differentially expressed or not). We
do not use a threshold to distinguish between highly and lowly
differentially expressed genes, because our method considers all
differential expression levels for computing the scores.
Scoring and ranking
For each candidate gene a score is computed based on the
differential expression levels of its neighborhood. For this purpose
the differential expression levels of all neighbors in the distance
network are ordered by their distance to the candidate gene. The
rank of the diffusion distance is then taken as the new distance
measure. The differential expression levels are then multiplied by a
weightingfunction (w~e{b:r, controlledby parameterb andrankr)
to stress expression of close neighbors and to suppress expression of
neighbors being far. Then the expression data is distributed
randomly over the network. The score for a candidate gene is
defined by the maximum deviation between its weighted neighbor-
ing expression and the randomized expression. Thus, the higher the
level of differential expression level of close neighboring genes, the
higher the score for the candidate gene (see Figure 3).
To obtain an empirical p-value for each candidate gene, the
distribution of the scores was determined by repeatedly (3,000
times) randomly distributing the expression data over the network
to estimate the significance of the signals of the actual candidates.
By comparing the score of each candidate gene with the random
distribution of the scores, a p-value was assigned. If a candidate’s
score was larger than 95% (a=0.05) of all randomized scores, this
candidate gene’s score was considered significant.
Neighborhood size
For our soft neighborhoods, we also define a notion of neighborhood
size. Instead of having a hard threshold on the distance that
determines whether a gene belongs to the neighborhood or not, our
weightingfunctionhasascaleparameterthatdetermineshowquickly
the weight decreases as a function of the distance. This parameter is
what defines our neighborhood ‘‘size’’. To communicate about the
neighborhood size easily, we use the following procedure. First, a
threshold on the weight is selected, meaning that we neglect the
contribution of all genes that have a weight lower than the threshold
and are thus sufficiently ‘‘far away’’ from the candidate (the number
of considered genes varies between 20 and 4000, depending on b that
varies from 0.001 and 0.5 (see Table S9)). As a result, we view the
genes for which the weight is considered nonnegligible as ‘‘inside’’ the
neighborhood. In our case, the weighting function is a negative
exponential function (w~e{b:r) regulated by a parameter b.A sb
decreases, the neighborhood size increases, and more neighboring
genes are considered for computing the scores of the candidates (see
Table S9).
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computed independently. Therefore, we first run the analysis for
various value of b (from 0.001 to 0.5) and, for each, measure the
signal captured by using the Fisher omnibus statistic
(S~
P
{2ln p{value ðÞ ) on the rankings produced. We then
generate a new p-value from the statistic S for each b using the x
2
distribution. The value of the parameter b with the smallest
corresponding p-value is considered the appropriate neighborhood
size for this data set. The idea is that, for an appropriate
neighborhood size, some of the candidates will capture meaningful
signal from their neighbors. By contrast, for inappropriate
neighborhood sizes, all candidates will have uniformly distributed
p-values, leading to a low statistic S.
Table S9 illustrates the signals derived by the Fisher omnibus
meta-analysis using the example of FXS [11], leading to an




# Mendelian disorder: fragile X syndrome (FXS, OMIM
#300624)
# Disease gene: fragile X mental retardation 1 (FMR1,
OMIM *309550)
# Phenotype: mental retardation, macroorchidism, and dis-
tinct facial features
# Expression data: Nishimura et al. (2007) [11] (GEO accession
number: GSE7316). Lymphoblastoid cell cultures from
patients with confirmed FMR1 full mutation (CGG repeat
expansion). Platform: Agilent-012391 Whole Human Ge-
nome Oligo Microarray G4112A
N MFS
# Mendelian disorder: Marfan syndrome (MFS, OMIM
#154700)
# Disease gene: fibrillin-1 precursor (FBN1, OMIM *134797)
# Phenotype: variable skeletal abnormalities, tall stature,
disproportionately long limbs and digits, joint laxity, eye
anomalies and progressive cardiovascular problems.
# Expression data: Yao et al. (2007) [12] (GEO accession
number GDS2960). Fibroblast cultures from patients with
confirmed FBN1 missense (9) and nonsense (7) mutations as
well as one multi-exon deletion. Platform: Research
Genetics (Invitrogen) - GF211 Microarray Filter
N CF
# Mendelian disorder: Cystic fibrosis (CF, OMIM #219700)
# Disease gene: Cystic fibrosis transmembrane conductance
regulator (CFTR, OMIM *602421, [43])
# Phenotype: chronic obstructive lung disease, bronchiectasia,
and exocrine pancreatic insufficiency
# Expression data: Wright et al. (2006) [13] (GEO accession
number GDS2143). Analysis of the nasal respiratory
epithelium of cystic fibrosis (CF) patients with mild (4) or
severe (5) lung disease. Platform: Affymetrix GeneChip
Human Genome U133 Array Set HG-U133B
N BMD
# Mendelian disorder: Becker muscular dystrophy (BMD,
OMIM #300376, [44])
# Disease gene: dystrophin (DMD, OMIM *300377)
# Phenotype: muscle wasting and weakness, and in some cases
with mental impairment.
# Expression data: Bakay et al. (2006) [14] (GEO accession
number GDS2855). Analysis of muscle biopsy specimens
from patients with various muscle diseases. Platform:
Affymetrix GeneChip Human Genome U133 Array Set
HG-U133B
N Stein-Levental syndrome
# Mendelian disorder: Stein-Levental syndrome ( OMIM
%184700)
# Putative disease genes: follistatin (FST (HGNC symbol),
OMIM *136470) putatively related with Stein-Levental
syndrome [24], fibrillin 3 (FBN3), OMIM *608529)
putatively associated with Stein-Levental syndrome [26].
# Phenotype: obesity, hyperandrogenism and chronic anovu-
lation
# Expression data: Corto ´n et al. (2007) [22] (GEO accession
number: GDS2084). Omental fat biopsy from patients.
Unconfirmed disorder etiology. Platform: Affymetrix Gen-
eChip Human Genome U133 Array Set HG-U133A
Figure 3. Level of differential expression as function of distance from the candidate for two different candidate genes. Gene A has a
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Figure S1 Neighborhood of FMR1 and DUSP9. These graphs
show the closest neighbors of FMR1 (A) and DUSP9 (B) including
their differential expression levels and distances to FMR1 and
DUSP9. For genes with absolute differential expression levels (2-
fold-changes) larger than 1.5, the nodes are labeled with the gene
names, the node size increases with the value and the color gets
darker. With decreasing distances (i.e., increasing similarities) the
edges between FMR1 or DUSP9 and their neighbors become
thicker. This picture shows that the neighborhood of FMR1
belongs to a more disrupted expression module than the
neighborhood of DUSP9.
Found at: doi:10.1371/journal.pone.0005526.s002 (2.11 MB TIF)
Figure S2 Neighborhood of FBN1 and LEO1. These graphs
show the closest neighbors of FBN1 (A) and LEO1 (B) including
their differential expression levels and distances to FBN1 and
LEO1. For genes with large absolute differential expression levels
(2-fold-changes), the nodes are labeled with the gene names, the
node size increases with the value and the color gets darker.With
decreasing distances (i.e., increasing similarities) the edges between
FBN1 or LEO1 and their neighbors become thicker. This picture
shows that the neighborhood of FBN1 belongs to a more disrupted
expression module than the neighborhood of LEO1.
Found at: doi:10.1371/journal.pone.0005526.s003 (2.43 MB TIF)
Figure S3 Neighborhood of CFTR and PIK3CG. These graphs
show the closest neighbors of CFTR (A) and PIK3CG (B)
including their differential expression levels and distances to
CFTR and PIK3CG. For genes with large absolute differential
expression levels (2-fold-changes), the nodes are labeled with the
gene names, the node size increases with the value and the color
gets darker. With decreasing distances (i.e., increasing similarities)
the edges between CFTR or PIK3CG and their neighbors become
thicker. This picture shows that the neighborhood of CFTR
belongs to a more disrupted expression module than the
neighborhood of PIK3CG.
Found at: doi:10.1371/journal.pone.0005526.s004 (2.22 MB TIF)
Table S1 Top 25 ranked candidate genes in Fragile X syndrome
(FXS). Fragile X syndrome [11] is a disorder caused by mutation
in the FMR1 gene, and is characterized by mental retardation,
macroorchidism, and distinct facial features. Candidate genes
were chosen from chrXq26-q28 that contains 119 genes including
FMR1. These candidate genes were ranked by our new approach,
and the top 25 ranked candidate genes are presented here,
whereas the top eleven genes have significant p-values (a=0.05).
FMR1 ranked first with a significant p-value (0.00131), and
FMR2, also involved in FXS, got a significant p-value of 0.01991
on position 6. Out of the eleven significant candidate genes in the
ranking we identified four genes, including FMR1 and FMR2,
that are known to be linked to mental retardation [11,15–17].
Found at: doi:10.1371/journal.pone.0005526.s005 (0.06 MB
DOC)
Table S2 Top 25 ranked candidate genes in Marfan syndrome
(MFS). Marfan syndrome [12] is a heritable connective tissue
disorder caused by mutations in the FBN1 gene, and is
characterized by increased height, disproportionately long limbs
and digits, anterior chest deformity, joint laxity, vertebral column
deformity, and other variable skeletal abnormalities, as well as
several ocular and cardiovascular features. Candidate genes were
chosen from 15q15.3-q22.33 that contains 129 genes including
FBN1. These candidate genes were ranked by our new approach,
and the top 25 ranked candidate genes are presented here,
whereas the top six genes have significant p-values (a=0.05).
FBN1 was ranked on the fifth position with a significant p-value
(0.0226). In the ranking we obtained six genes that were significant
but not involved in MFS or phenotype related diseases.
Found at: doi:10.1371/journal.pone.0005526.s006 (0.06 MB
DOC)
Table S3 Top 25 ranked candidate genes in Cystic fibrosis (CF).
Cystic fibrosis [13] is an autosomal recessive disorder of epithelial
ion transport caused by mutations in the CF transmembrane
conductance regulator gene (CFTR), and is characterized by
chronic obstructive lung disease, bronchiectasia, and exocrine
pancreatic insufficiency. Candidate genes were chosen from
chr7q22.1-31.33 that contains 110 genes including CFTR. These
candidate genes were ranked by our new approach, and the top 25
ranked candidate genes are presented here, whereas the top nine
genes have a significant p-value (a=0.05). CFTR was ranked in
the seventh position with a significant p-value (0.046). In the
ranking we obtained seven genes that were significant but not
involved in CF or phenotype related diseases. However, out of the
top 25 ranked genes we detected four genes that are known to be
linked to CF [18–21].
Found at: doi:10.1371/journal.pone.0005526.s007 (0.06 MB
DOC)
Table S4 Top 25 ranked candidate genes in Becker muscular
dystrophy (BDM). Becker muscular dystrophy [14] is a X-linked
progressive myopathy caused by mutations within the DMD gene,
and is characterized by muscle wasting and weakness, and in some
cases with mental impairment. Candidate genes were chosen from
chrXp22.33-21.1 that contains 116 genes including DMD. These
candidate genes were ranked by our new approach, and the top 25
ranked candidate genes are presented here, whereas the top two
genes have significant p-values (a=0.05). DMD ranked on the
second position with a significant p-value (0.0272). The other
significant gene is not involved in BMD or in a phenotype related
disease.
Found at: doi:10.1371/journal.pone.0005526.s008 (0.06 MB
DOC)
Table S5 Top 25 ranked candidate genes from chr5q11.2 in
Stein-Levental syndrome. Stein-Levental syndrome [22] is a
oligogenic hormonal disorder among women putatively related
with the FST gene, and is characterized by hyperandrogenism,
chronic anovulation and associated with obesity. Candidate genes
were chosen from chr5q11.2 that contains 25 genes including the
candidate gene FST [24]. These candidate genes were ranked by
our new approach, whereas only the top gene has a significant p-
value (a=0.05). FST was ranked in the second position with a p-
value of 0.056, and we received only one significant gene (DEAD
box 4) that is a plausible candidate gene for Stein-Levental
syndrome.
Found at: doi:10.1371/journal.pone.0005526.s009 (0.06 MB
DOC)
Table S6 Top 25 ranked candidate genes from chr19p13.2 in
Stein-Levental syndrome. Stein-Levental syndrome [22] is a
oligogenic hormonal disorder among women putatively associated
with the FBN3 gene, and is characterized by hyperandrogenism,
chronic anovulation and associated with obesity. Candidate genes
were chosen from chr19p13.2 that contains 100 genes including
the candidate gene FBN3 [26]. These candidate genes were
ranked by our new approach, and the top 25 ranked candidate
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significant p-value (a=0.05). FBN3 was ranked in the fifth
position with a p-value of 0.0595.
Found at: doi:10.1371/journal.pone.0005526.s010 (0.06 MB
DOC)
Table S7 CPU times for computing the Laplacian Exponential
Diffusion Kernel by its definition, the CD and the ICD. CPU
times (sec) for computing the Laplacian Exponential Diffusion
Kernel by its definition (Equation 1), by CD (Equation 2), and by
ICD (Equation 3) with a threshold leading to an error of 7%–10%.
The computation were run on a dual Opteron 250 with 16 GB
RAM.
Found at: doi:10.1371/journal.pone.0005526.s011 (0.03 MB
DOC)
Table S8 Rank and Error of resulting Laplacian Exponential
Diffusion Kernel computed by its definition, the CD and the ICD.
Rank and Error of resulting Laplacian Exponential Diffusion
Kernel computed by its definition, (Equation 1), by CD (Equation
2), and by ICD (Equation 3) with a threshold leading to an error of
7%–10%. The computation were run on a dual Opteron 250 with
16 GB RAM.
Found at: doi:10.1371/journal.pone.0005526.s012 (0.03 MB
DOC)
Table S9 Example for determining an appropriate neighbor-
hood size using the example of data set 1 (FXS [11]). The
neighborhood size is controlled by a weighting function
(w=exp(2b?r). Applying the Fisher omnibus meta-analysis
(S=g22 ln (p-value)) for each parameter b, new p-values are
generated from a X‘2 distribution. The parameter b , for which
the smallest p-value is observed (here: b=0.05), leads to the
appropriate neighborhood size for FXS (approx. 150 genes).
Found at: doi:10.1371/journal.pone.0005526.s013 (0.02 MB
DOC)
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